opiranserin opiranserin opiranserin (inn; developmental code name vvz-149) is a selective and combined glycine glyt2 transporter blocker (ic50 = 0.86 μm), purine p2x3 receptor antagonist (ic50 = 0.87 μm), and serotonin 5-ht2a receptor antagonist (ic50 = 1.3 μm) which is under development by vivozon for the intravenous treatment of postoperative pain. as of april 2017, it is in phase ii clinical trials for this indication. the inn of the drug was issued in 2017. opiranserinclinical dataother namesvvz-149; vvz-000149routes ofadministrationintravenousidentifiers iupac name 4-butoxy-n-(methyl)-3,5-dimethoxybenzamide cas number1441000-45-8pubchem cid71566778uniiap031ec2nichemical and physical dataformulac21h34n2o5molar mass394.512 g·mol−13d model (jsmol)interactive image smiles o=c(ncc1(n(c)c)ccocc1)c2=cc(oc)=c(occcc)c(oc)=c2 inchi inchi=1s/c21h34n2o5/c1-6-7-10-28-19-17(25-4)13-16(14-18(19)26-5)20(24)22-15-21(23(2)3)8-11-27-12-9-21/h13-14h,6-12,15h2,1-5h3,(h,22,24)key:jquvqwmhzsycrq-uhfffaoysa-n